← ANALYST RATINGS · TIPRANKS
Achieve Life Sciences (ACHV): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $13.83, the highest $18.00, the lowest $10.00. The average is +116.8% from the last price of $6.38.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 → $6.00−20.0% | Hold | −6.0% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 → $6.50−13.3% | Hold | +1.9% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 → $6.50−13.3% | Hold | +1.9% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $6.50−13.3% | Hold | +1.9% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 → $6.50−13.3% | Hold | +1.9% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $6.50−13.3% | Hold | +1.9% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% | Stifel Nicolaus | $18.00 | Buy | +182.1% | Initiated | 30.09.26on TipRanks Sep 29 16:25 | +5.4%next day −7.1% · 5 days −12.4% | ↗ |
| Patrick Dolezal★★★★★★★★★★#1287 · hits 44% · avg +15.1% | LifeSci Capital | $17.00 | Buy | +166.5% | Reiterated | 03.09.26on TipRanks 17:05 | +2.6%next day −7.1% · 5 days −13.6% | ↗ |
| Maxwell Skor★★★★★★★★★★#486 · hits 74% · avg +28.0% | Morgan Stanley | $13.00 | Buy | +103.8% | Initiated | 13.08.26on TipRanks 05:25 | +7.7%next day +4.9% · 5 days +12.6% | ↗ |
| Jason McCarthy★★★★★★★★★★#12398 · hits 30% · avg −13.6% | Maxim Group | $10.00 | Buy | +56.7% | Reiterated | 12.08.26on TipRanks Aug 13 13:55 | −1.4%next day +7.7% · 5 days +27.9% | ↗ |
| Gary Nachman★★★★★★★★★★#7384 · hits 47% · avg +0.3% | Canaccord Genuity | $13.00 | Buy | +103.8% | Reiterated | 12.08.26on TipRanks 07:15 | −1.4%next day +7.7% · 5 days +27.9% | ↗ |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $12.00 | Buy | +88.1% | Reiterated | 11.08.26on TipRanks 13:35 | +1.8%next day −1.4% · 5 days +11.5% | ↗ |
| Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% | Raymond James | $20.00 | Buy | +213.5% | Initiated | 26.06.26on TipRanks 08:20 | +6.3%next day +1.8% · 5 days +4.1% | ↗ |
| Mark Smith★★★★★★★★★★#1621 · hits 47% · avg +8.7% | Lake Street | $11.00 | Buy | +72.4% | Reiterated | 13.05.26on TipRanks 09:15 | −1.1%next day −3.6% · 5 days −23.2% | ↗ |
| Justin Walsh★★★★★★★★★★#640 · hits 39% · avg +20.6% | JonesTrading | $20.00 | Buy | +213.5% | Reiterated | 12.05.26on TipRanks 13:30 | +7.3%next day −1.1% · 5 days −25.1% | ↗ |
| Jason Butler★★★★★★★★★★#412 · hits 51% · avg +18.3% | Citizens JMP | $19.00 | Buy | +197.8% | Initiated | 25.11.25on TipRanks 05:20 | +14.7%next day +4.8% · 5 days +5.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Achieve Life Sciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $13.83 at a price of $8.09 (+71.0%); now: $13.83 at $6.38 (+116.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 15 | 10 | 11 | 9 | 9 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.20 (from $-0.36 to $-0.11). Last quarter: $-0.80.
Best top-analyst consensus in the sector · Healthcare
About Achieve Life Sciences
- CEO: Andrew D. Goldberg
- Employees: 28
- 22722 29th Dr. SE, Bothell, WA, 98021, US
- www.achievelifesciences.com
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Data from the stock’s TipRanks forecast page, read 120 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗